RAPT Therapeutics (RAPT) Total Current Liabilities (2020 - 2024)
Historic Total Current Liabilities for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $10.4 million.
- Therapeutics' Total Current Liabilities fell 5257.45% to $10.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.4 million, marking a year-over-year decrease of 5257.45%. This contributed to the annual value of $21.8 million for FY2023, which is 5351.52% up from last year.
- According to the latest figures from Q3 2024, Therapeutics' Total Current Liabilities is $10.4 million, which was down 5257.45% from $14.8 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Total Current Liabilities registered a high of $21.8 million during Q3 2023, and its lowest value of $9.6 million during Q4 2021.
- Over the past 5 years, Therapeutics' median Total Current Liabilities value was $13.4 million (recorded in 2020), while the average stood at $14.6 million.
- Per our database at Business Quant, Therapeutics' Total Current Liabilities skyrocketed by 7482.2% in 2023 and then plummeted by 5257.45% in 2024.
- Therapeutics' Total Current Liabilities (Quarter) stood at $11.7 million in 2020, then fell by 18.28% to $9.6 million in 2021, then surged by 48.24% to $14.2 million in 2022, then soared by 53.52% to $21.8 million in 2023, then crashed by 52.55% to $10.4 million in 2024.
- Its last three reported values are $10.4 million in Q3 2024, $14.8 million for Q2 2024, and $21.2 million during Q1 2024.